Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
There are almost always some companies doing well, even when competitors in the same industry are sinking. Right…
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
The telehealth company Hims & Hers (NYSE: HIMS), which provides consultations and prescriptions, saw its stock crater by…
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly’s (NYSE: LLY) stock has risen 225% over the past three years. That trounces the S&P 500’s (SNPINDEX:…
The most controversial Super Bowl ad of 2025 is back for more
Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…
Novo Nordisk says Hims & Hers’ cheaper version of Wegovy pill is illegal
In an unexpected move, Hims & Hers is making available a cheaper, compounded version of the Wegovy weight…
Hims and Hers Health’s compounded Wegovy pill offering fuels market jitters
Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…
Hims launches $49 compounded copy of Wegovy weight-loss pill
By Amina Niasse NEW YORK, Feb 5 (Reuters) – Online telehealth company Hims and Hers Health will start…
Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
Novo’s Wegovy pill tracks over 26,000 prescriptions
Jan 30 (Reuters) – Novo Nordisk’s Wegovy pill hits over 26,000 U.S. prescriptions in the second full week…
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s new once-daily pill for weight management, designed…
Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss
This article first appeared on GuruFocus. Roche Holding AG (RHHBY) is beginning to show tangible progress in obesity…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…